Videos

Switching to a patient scenario of metastatic hormone-sensitive prostate cancer, experts discuss which therapeutic approach they would undertake.

A brief discussion on the role of PSMA-targeted therapy’s role in managing patients with nonmetastatic castration-resistant prostate cancer.

Scott T. Tagawa, MD, spoke about potential approvals in the coming year for prostate cancer.

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.

An explanation of dosing strategies when treating patients with renal cell carcinoma in the first-line with lenvatinib.

Experts discuss the safety of treating renal cell carcinoma with lenvatinib within different patient risk populations.

Possible comorbidities and other risk factors in advanced renal cell carcinoma that would affect potential treatment regimens.

Lori Wirth, MD, discusses the role of cabozantinib in the second-line setting for patients with radioiodine-refractory differentiated thyroid cancer and reviews the results from the COSMIC-311 trial.

Key takeaways from the CARTITUDE-1 study and the KarMMA study evaluating CAR T-cell therapies for relapsed/refractory multiple myeloma.

An overview of BCMA-targeting bispecific agents in development for multiple myeloma, including talquetamab and teclistamab.

A panel of doctors discuss the available treatment options for early and late relapsed multiple myeloma, including approved novel BCMA-targeting agents.

A look at the patient outcomes with daratumumab use in the frontline vs second-line setting in patients with transplant-ineligible multiple myeloma, and the pros and cons of subcutaneous vs intravenous daratumumab.

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

David Aggen, MD, PhD identifies patient populations who may benefit from single-agent therapy and reviews NCCN recommendations for first-line treatment of metastatic clear cell RCC.

Robert Alter, MD, weighs in on the evolution of combination therapy as the first-line standard of care for patients with metastatic clear cell RCC.

Sam Klempner, MD, spoke about the importance of expanding minimal residual disease platforms for patients with gastrointestinal cancers.

David Aggen, MD, PhD touches on the availability of newer first-line combination treatment options for metastatic disease.

Robert Alter, MD compares older, single-agent first line therapies for patients with metastatic clear cell RCC.

Dr Sara Hurvitz provides an overview of HER2+ breast cancer, and Dr Ruta Rao details the frontline treatment options available for metastatic cases.

Ruta Rao, MD, presents the case of a 36-year-old woman with metastatic HER2+ breast cancer and brain metastases.

Experts share their excitement for upcoming PFS trial data to be presented on the combination of ixazomib, pomalidomide, and dexamethasone in multiple myeloma.

Before closing out their discussion on intermediate-risk RCC, experts review frontline triplet combinations and possible treatment options following relapse after nivolumab-ipilimumab.

Comprehensive discussion on how to best treat patients with renal cell carcinoma and brain or bone metastasis.

Brian Slomovitz, MD, spoke about previously conducted trials that used regimens involving pembrolizumab and chemotherapy for patients with newly diagnosed high-risk endometrial cancer at SGO 2022.

Nicolas Girard, MD, highlighted key findings from the CheckMate 816 trial, examining nivolumab and chemotherapy vs chemotherapy alone in resectable non–small cell lung cancer.

Frederick Lock, MD, spoke about how axicabtagene ciloleucel has improved survival in patients with large B-cell lymphoma.

Gennady Bratslavsky, MD, spoke about the role of adjuvant therapy in renal cell carcinoma at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies.

Petros Grivas, MD, PhD, introduces a patient profile of a woman with metastatic UC and invites panel members to comment on how they might approach initial treatment and management of the patient.

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Petros Grivas, MD, PhD, Shilpa Gupta, MD, Peter H. O’Donnell, MD, Thomas Powles, MBBS, MRCP, MD, and Guru Sonpavde, MD, summarize recent treatment advances for patients with urothelial cancer (UC).